The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | An insight into Langerhans cell histiocytosis and advances in treatment approaches
Roei Mazor
• 10 Jun 2022
Roei Mazor, MD, PhD, Assuta Medical Center, Tel Aviv, Israel, shares some insights into the treatment of Langerhans cell histiocytosis. Dr Mazor first provides some background on the biology of this rare disease, and then goes on to explain how treatment approaches for Langerhans cell histiocytosis have improved due to a better understanding of driver mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
